Increased risk of multiple sclerosis relapse after in vitro fertilisation

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 83, Issue 8, 2012, Pages 796-802

  Michel, Laure ^a,b   Foucher, Yohann ^b,c   Vukusic, Sandra ^d   Confavreux, Christian ^d   De Sèze, Jérome ^e   Brassat, David ^f   Clanet, Michel ^f   Clavelou, Pierre ^g   Ouallet, Jean Christophe ^h   Brochet, Bruno ^h   Pelletier, Jean ⁱ   Labauge, Pierre ^j   Lebrun, Christine ^k   Lepage, Emmanuelle ^l   Le Frere, Fabienne ^a   Jacq Foucher, Marylène ^a   Barriere, Paul ^m   Wiertlewski, Sandrine ^a   Laplaud, David Axel ^a,b  

^a CHU de Nantes   (France)

^b INSERM   (France)

^c Universite de Nantes   (France)

^d UNIVERSITÉ LYON 1   (France)

^e UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^f TOULOUSE UNIVERSITY HOSPITAL   (France)

^g SERVICE DE RHUMATOLOGIE   (France)

^h HÔPITAL PELLEGRIN   (France)

ⁱ TIMONE HOSPITAL   (France)

^j DEPARTMENT OF NEUROLOGY   (France)

^k UNIVERSITY HOSPITAL OF NICE   (France)

^l PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^m NANTES UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA1 INTERFERON; CORTICOSTEROID; GLATIRAMER; GONADORELIN AGONIST; GONADORELIN ANTAGONIST;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE EXACERBATION; DOSE RESPONSE; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PREGNANCY RATE; PRIORITY JOURNAL; RECURRENCE RISK; RISK FACTOR;

ADULT; AGE OF ONSET; FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HUMANS; MULTIPLE SCLEROSIS; MULTIVARIATE ANALYSIS; PREGNANCY; RECURRENCE; RISK FACTORS; STATISTICS, NONPARAMETRIC;

EID: 84863888096     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2012-302235     Document Type: Article

References (26)

1. Debouverie M. Gender as a prognostic factor and its impact on the incidence of multiple sclerosis in Lorraine, France. J Neurol Sci 2009;286:14-17.
2. Alonso A, Hernan MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 2008;71:129-35.
3. Straub RH. The complex role of estrogens in inflammation. Endocr Rev 2007;28:521-74.
4. Tintore M, Arrambide G. Early onset multiple sclerosis: the role of gender. J Neurol Sci 2009;286:31-4.
5. Confavreux C, Hutchinson M, Hours MM, et al. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 1998;339:285-91.
6. Vukusic S, Hutchinson M, Hours M, et al; The Pregnancy in Multiple Sclerosis Group; Pregnancy in Multiple Sclerosis Group. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 2004;127:1353-60.
7. Alonso A, Jick SS, Olek MJ, et al. Recent use of oral contraceptives and the risk of multiple sclerosis. Arch Neurol 2005;62:1362-5.
8. Sicotte NL, Liva SM, Klutch R, et al. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol 2002;52:421-8.
9. Runmarker B, Andersen O. Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis. Brain 1995;118:253-61.
10. Laplaud DA, Leray E, Barriere P, et al. Increase in multiple sclerosis relapse rate following in vitro fertilization. Neurology 2006;66:1280-1.
11. Hellwig K, Beste C, Brune N, et al. Increased MS relapse rate during assisted reproduction technique. J Neurol 2008;255:592-3.
12. Hellwig K, Schimrigk S, Beste C, et al. Increase in relapse rate during assisted reproduction technique in patients with multiple sclerosis. Eur Neurol 2009;61:65-8.
13. Confavreux C, Compston DA, Hommes OR, et al. EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry 1992;55:671-6.
14. Rudick R, Antel J, Confavreux C, et al. Clinical outcomes assessment in multiple sclerosis. Ann Neurol 1996;40:469-79.
15. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005;58:840-6.
16. EMA. Guideline on clinical trials in small populations. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/WC500003615.pdf (accessed 10 Apr 2012).
17. Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. Springer-Verlag, New-York-Berlin-Heidelberg, 2000.
18. Grambsch P, Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;81:515-26.
19. Mitsonis CI, Potagas C, Zervas I, et al. The effects of stressful life events on the course of multiple sclerosis: a review. Int J Neurosci 2009;119:315-35.
20. Mohr DC, Hart SL, Julian L, et al. Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis. BMJ 2004;328:731.
21. Chen A, Ganor Y, Rahimipour S, et al. The neuropeptides GnRH-II and GnRH-I are produced by human T cells and trigger laminin receptor gene expression, adhesion, chemotaxis and homing to specific organs. Nat Med 2002;8:1421-6.
22. Batticane N, Morale MC, Gallo F, et al. Luteinizing hormone-releasing hormone signaling at the lymphocyte involves stimulation of interleukin-2 receptor expression. Endocrinology 1991;129:277-86.
23. Jacobson JD, Ansari MA, Kinealy M, et al. Gender-specific exacerbation of murine lupus by gonadotropin-releasing hormone: potential role of G alpha(q/11). Endocrinology 1999;140:3429-37.
24. Jacobson JD, Nisula BC, Steinberg AD. Modulation of the expression of murine lupus by gonadotropin-releasing hormone analogs. Endocrinology 1994;134:2516-23.
25. Marchetti B, Guarcello V, Morale MC, et al. Luteinizing hormone-releasing hormone (LHRH) agonist restoration of age-associated decline of thymus weight, thymic LHRH receptors, and thymocyte proliferative capacity. Endocrinology 1989;125:1037-45.
26. Borm G, Mannaerts B. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. Hum Reprod 2000;15:1490-8.